NasdaqCM - Delayed Quote • USD
Galectin Therapeutics Inc. (GALT)
At close: April 18 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -0.16 | -0.16 | -0.66 | -1.59 |
| Low Estimate | -0.16 | -0.16 | -0.66 | -1.59 |
| High Estimate | -0.16 | -0.16 | -0.66 | -1.59 |
| Year Ago EPS | -0.19 | -0.15 | -0.74 | -0.66 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -- | -- | -- | 36.32M |
| Low Estimate | -- | -- | -- | 36.32M |
| High Estimate | -- | -- | -- | 36.32M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.21 | -0.21 | -0.16 | -0.16 |
| EPS Actual | -0.19 | -0.15 | -0.24 | -0.16 |
| Difference | 0.02 | 0.06 | -0.08 | 0 |
| Surprise % | 9.50% | 28.60% | -50.00% | 0.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.16 | -0.16 | -0.66 | -1.59 |
| 7 Days Ago | -0.16 | -0.16 | -0.66 | -1.59 |
| 30 Days Ago | -0.16 | -0.16 | -0.66 | -1.37 |
| 60 Days Ago | -0.16 | -0.16 | -0.66 | -1.37 |
| 90 Days Ago | -0.16 | -0.16 | -0.66 | -1.37 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | GALT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 15.80% | -- | -- | 0.80% |
| Next Qtr. | -6.70% | -- | -- | 9.60% |
| Current Year | 10.80% | -- | -- | 4.50% |
| Next Year | -140.90% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/9/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/1/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/15/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/17/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 3/3/2023 |
| Maintains | HC Wainwright & Co.: Buy | 5/17/2022 |
Related Tickers
MDGL Madrigal Pharmaceuticals, Inc.
222.26
-2.66%
GLMD Galmed Pharmaceuticals Ltd.
0.3787
+6.05%
CRDF Cardiff Oncology, Inc.
4.3700
-2.89%
LPCN Lipocine Inc.
5.44
+2.26%
RZLT Rezolute, Inc.
3.3000
+1.85%
ENTX Entera Bio Ltd.
2.2400
+0.90%
BIXT Bioxytran, Inc.
0.1285
+4.47%
GLYC GlycoMimetics, Inc.
2.1600
-5.26%
ALT Altimmune, Inc.
6.89
-2.13%
CDXS Codexis, Inc.
2.8000
+1.45%